检索历史 清除

本文摘要回顾了2024年ASCO-GU会议上关于尿路上皮癌的最新研究，主要讨论了淋巴结阳性肌层浸润性膀胱癌(N ＋ MIBC)的治疗策略和MIBC术后的辅助治疗。N ＋ MIBC患者面临较高的复发风险，需要综合治疗策略。新辅助化疗和免疫治疗的联合方案显示出显著的疗效，此外，保留膀胱治疗和免疫维持治疗在延长无病生存期方面展现出潜力。AMBASSADOR和CheckMate-274研究的结果显示，高危MIBC术后免疫辅助治疗有利于延缓疾病复发。这些进展为高危MIBC患者的治疗提供了新的希望，并可能改善患者的预后。

This article reviews the latest research on urothelial carcinoma presented at the 2024 ASCO-GU conference, focusing primarily on the treatment strategies for node-positive muscle-invasive bladder cancer (N + MIBC) and adjuvant therapy post-surgery for muscle-invasive bladder cancer. Patients with N + MIBC are at a higher risk of recurrence and require a comprehensive treatment approach. The combination of neoadjuvant chemotherapy and immunotherapy has demonstrated significant efficacy. Additionally, bladder-sparing treatment and immuno-maintenance therapy show promise in improving disease-free survival. The results from the AMBASSADOR and CheckMate-274 studies indicate that postoperative immuno-adjuvant therapy for high-risk MIBC is beneficial in delaying disease recurrence. These advancements offer new hope for the treatment of patients with high-risk MIBC and may potentially improve patient outcomes.